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Abstract 
Adipose tissue displays characteristics of an endocrine organ releasing a number of adipocyte-specific factors known as 
adipocytokines.  It has been recently suggested that adipocytokines may play a role in pathogenesis and progression of certain 
cancers, in particular in colorectal cancer. The aim of this study was to investigate the association between several blood 
adipocytokine levels and clinicopathological characteristics of colon cancer patients undergoing surgery. The study group comprised 
of 29 patients who underwent surgical resection for colon cancer at Emergency University Hospital Bucharest and 27 healthy 
volunteers. The serum levels of adipocytokines were measured using multianalyte xMap profiling technology (Luminex). Resistin 
levels were significantly higher in colon cancer patients while leptin serum levels were significantly lower as compared to controls. 
Leptin levels decreased gradually with tumor stage and aggressiveness. Taken together, these results of this study suggest that 
adipokines, in particular resistin and leptin may be involved in development and progression of colon cancer. 
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Introduction 
In the past decade it has become increasingly 
clear that adipose tissue displays characteristics of an 
endocrine organ releasing a number of adipocyte-specific 
factors known as adipocytokines [1,2]. It has been 
recently suggested that adipocytokines, such as TNF-
alpha, IL-6, type-1 plasminogen activator inhibitor (PAI-1), 
adiponectin, leptin, resistin, visfatin and apelin are 
associated with the risk of cancer at various sites (e.g., 
breast, prostate gland, endometrium and colorectum) [3-
6]. This might partially explained the epidemiological 
evidence of obesity-related carcinogenesis. The altered 
secretion of metabolically active, proinflammatory 
adipocytokines from adipose tissue is believed to play a 
key role in the mechanisms relating obesity and cancer, 
which are only started to be uncovered [7]. Moreover, 
obesity is associated with a state of chronic low level 
inflammation, characterized by abnormal cytokine 
production which might affect both tumor initiation and 
tumor progression, such as adipocyte-conditioned 
medium can e.g. promote tumor migration [1,8].  
Although a strong association between the 
prevalence of colorectal adenomas and increased levels 
of proinflammatory cytokines such as IL-6 and TNF-alpha 
has been documented, [9] there are contradictory reports 
in the literature regarding the role of “classical” 
adipocytokines such as leptin, adiponectin or resistin in 
this pathology. For example, in several studies, a 
significant increase in colon cancer risk with increasing 
serum leptin concentrations was reported [7,10] while 
others reported significantly lower leptin levels in cancer 
patients relative to controls [11]. Elevated levels of plasma 
resistin have been found in breast cancer [12] and in non-
small cell lung cancer patients [13]. As it has been shown 
that resistin is produced by the stromovascular fraction of 
adipose tissue and peripheral blood monocytes, 
increased resistin levels in cancer patients was explained 
not only by the adipose tissue involvement but also by the 
activation of monocytes as part of the generalized 
inflammatory process. In one study, increased resistin 
and low adiponectin serum levels negatively correlated 
with the stage were reported in colorectal cancer [5]. Also, 
an upregulation in 92% of the samples in the levels of 
resistin protein in colon cancer tissue was observed [14]. 
Collectively, these studies suggest a possible role of Journal of Medicine and Life Vol. 3, No.4, October‐December 2010 
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adipokines in pathogenesis and progression of certain 
cancers, in particular of colorectal cancer. 
The aim of this study was to investigate the 
association between several blood adipocytokine levels 
and clinicopathological characteristics of colon cancer 
patients undergoing surgery.  
Materials and methods 
Study population  
The study group comprised of 29 patients who 
underwent surgical resection for colon cancer at 
Emergency University Hospital Bucharest (Department of 
General Surgery, Division II) and 27 healthy volunteers. 
All subjects (patients and controls) provided informed 
consent prior to the collection and analysis of blood 
samples and the study was approved by local Ethics 
Committee.    
 
Adipocytokines measurements 
Blood samples were collected from colon cancer 
patients before and after surgery. Whole blood was 
allowed to clot for 1 hour at 37°C and spun to serum 
(quick run). Serum was aliquoted and stored at -20°C 
until analyzed. The following adipocykines were tested in 
serum samples: adiponectin, leptin, resistin and 
serpin/type-1 plasminogen activator inhibitor (PAI-1) using 
Human Obesity Multianalyte Profiling Base Kit and 
Fluorokine MAP Human microbeads for each of the above 
mentioned parameters (R&D Systems Inc., Minneapolis, 
USA) following the protocol described in detail elsewhere 
[15]. Plate reading was performed on the Luminex® 
200™ platform (purchased from Luminex Corporation, 
Austin, TX, USA) and data were processed with 
Luminex® 200™ IS 2.3 Star Station software (Applied 
Cytometry, Plano, TX, USA). 
 
Statistical Analysis  
Statistical analysis was performed using R 
software [16]. Serum levels of individual adipocytokines 
between groups were compared by the nonparametric 
two-tailed Wilcoxon signed-rank test (unpaired for testing 
differences between groups and paired for the same 
group at different time points). Correlations between 
individual cytokine levels were analyzed by the 
nonparametric Spearman’s correlation test. A P-value 
<0.05 were considered to be statistically significant. 
Results 
Table 1 shows the clinical characteristics of the 
patients and the controls. There was no significant 
difference in age and sex between the 2 groups.
 
 
 
 
Characteristic  Patients 
(n=31) 
Controls 
(n=27) 
P 
Age (mean SD, range)  63  13 (27-84)  59.1  14.8 (23-89)  0.21 
Sex 
female 
male 
 
12 
17 
 
15 
12 
 
 
 
Tumor location 
ascending colon 
transverse colon 
descending colon 
sigmoid colon 
 
7 
1 
7 
14 
 
 
 
 
 
 
 
 
 
 
Tumor stage (Dukes’) 
B1 
B2 
C 
D 
Not known 
 
 2 
17 
7 
1 
2 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor differentiation 
Poorly differentiated 
Moderately diff.  
Well differentiated 
Mucinous 
Not known 
 
7 
15 
2 
3 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
The adipokines concentration were measured in 
patients’ serum at two time points: 3-4 days before 
surgery (time point 1: “preop”), and 5-7 days after surgery 
(time point 2: “postop”). The concentration of adiponectin 
and PAI-1 in undiluted serum was above the upper limit of 
linearity of the test for both patients and controls. 
Therefore, we decided to examine comparatively, only the 
concentration of resistin and leptin, which did not exceed 
Table 1. Clinical characteristics of patients and controls Journal of Medicine and Life Vol. 3, No.4, October‐December 2010 
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the measurable range of the test in undiluted sera of 
patients and controls.  
  As can be seen in (Figure 1), serum leptin levels 
measured both before and after surgery were significantly 
lower in patients compared to healthy controls (P=0.01 
and  P<0.001, respectively). Moreover, a statistically 
significant decrease of leptin concentration was noted 
after surgery as compared to presurgical levels (P<0.01). 
By contrast, resistin serum levels in colon cancer patients 
were significantly higher as compared to controls, both 
pre- and post operatively (P<0.001 in both cases) (Figure 
2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, for both mediators, we noticed a 
statistically significant positive correlation between 
preoperative and postoperative values (r=0.408, P<0.05 
for resistin and r=0.701, P<0.001 for leptin).  
Next, we looked for possible association 
between measured adipokines serum levels and 
clinicopathological features such as tumor stage, 
histological grade of differentiation or localization.  There 
was no statistically significant difference in serum 
concentration of resistin or leptin between A+B vs. C+D 
Dukes’ stage (Table 2).  
 
 
 
Dukes’ B1+B2 
(n=19) 
Dukes’ C+D 
 (n=8) 
 
 
  Mean  SD        Med (Min, max)  Mean  SD        Med (Min, max) 
Resistin*  27.25  16.3  32.51 (6.13, 46.4)  27.45  19.46  20.2 (1.84, 87.6) 
Leptin**  11.99  16.2  8.17 (1.33, 50.94)  12.62  15.8  5.3 (0.38, 53.6) 
* P<0.01, Dukes’ B1+B2 carcinoma vs. controls 
   NS, Dukes’ B1+B2 vs. Dukes’ C+D 
   P<0.001, Dukes’ C+D vs. controls 
 
** NS, Dukes’ B1+B2 vs. controls 
    NS, Dukes’ B1+B2 vs. Dukes’ C+D 
    P<0.05, Dukes’ C+D vs. controls 
 
As it can be seen, for both subgroups of patients, 
serum resistin levels were significantly higher as 
compared to controls (P<0.01 for Dukes’ B1+B2 stages 
and  P<0.001 for Dukes’ C+D stages). Leptin serum 
concentration was significantly decreased than those in 
controls only in patients in more advanced stages (P<0.05 
as compared to controls). Moreover, a significant negative 
correlation was present between leptin and T stage (r=-
0.218, P=0.021, Spearman); however no correlation was 
noticed between leptin concentration and Dukes’ stage.  
Disease stage and resistin displayed no correlation.  
  Although a trend toward higher values was 
noticed for both tested mediators in patients with well and 
moderately differentiated tumors versus poorly 
differentiated or mucinous colon adenocarcinoma, the 
differences did not reach the statistical significance (Table 
3). When compared control values, resistin levels were 
significantly higher in both patients’ subgroups, while 
leptin levels were significantly lower only in the subgroup 
of patients with poorly differentiated (including the three 
patients with mucinous adenocarcinoma).  
Fig.1 Box plots representing serum leptin levels in patients 
with colon cancer before surgery (preop) and after surgery 
(postop) and controls.  
*P < 0.05 vs controls 
**P < 0.01 vs controls 
§ P < 0.01 vs preop, two-tailed Wilcoxon signed-rank test. 
 
Fig.2  Box plots representing serum resistin levels in 
patients with colon cancer before surgery (Pre-op) and 
after surgery (Post-op) and controls.  
*P < 0.001 vs controls, two-tailed Wilcoxon signed-rank 
test. 
Table 2.  Serum adipokines concentration and P value in colon cancer patients according to tumor stage Journal of Medicine and Life Vol. 3, No.4, October‐December 2010 
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Well and moderately differentiated 
(n=17) 
Poorly differentiated + Mucinous 
(n=10) 
 
 
  Mean  SD        Med (Min, max)  Mean  SD        Med (Min, max) 
Resistin*  30.91  19.93  24.7 (6.13, 87.6)  21.41  13.95  18.2 (1.84, 46.4) 
Leptin**  15.12  18.5  24.7 (0.71, 53.6)  7.86  7.6  5.31 (0.38, 23.4) 
 
* P<0.00001, Well/ Mod. differentiated carcinoma vs. controls 
   NS, Well/ Mod. differentiated carcinoma vs. Poorly differentiated + Mucinous carcinoma 
  P<0.01, Poorly differentiated + Mucinous carcinoma vs. controls 
 
** NS, Well/ Mod. differentiated carcinoma vs. controls 
     NS, Well/ Mod. differentiated carcinoma vs. Poorly differentiated + Mucinous carcinoma 
    P<0.05, Poorly differentiated + Mucinous carcinoma vs. controls 
 
No significant differences in adipokines serum 
concentration according to tumor localization were noticed 
(P>0.05).  
Discussion 
The aim of this study was to determine the 
correlation, if any, between clinicopathological features of 
patients with colon cancer undergoing surgery and the 
serum level of adipokines.  
We observed that circulating resistin levels were 
significantly increased in colon cancer patients as 
compared to controls. These results are in agreement 
with other studies which found higher levels of resistin in 
patients with colorectal [5,11], breast [6] or non-small cell 
lung cancer [13]. Nakajima et al. reported that resistin 
levels were significantly higher in colorectal cancer 
patients than those in controls independent of the BMI, 
and these levels gradually increased with progression in 
tumor stage [17]. In our study, although colon cancer 
patients displayed increased serum resistin levels, we did 
not obtain any correlation between serum levels of resistin 
and tumor stage, localization or grade of differentiation. 
This discrepancy might be explained by the limited 
number of patients in advanced stage of disease (n = 8 in 
Dukes’ C+D stages).   
It has been suggested that high resistin levels 
are related to cancer associated chronic inflammation. 
Recent data indicate that stimulation of macrophages in 
vitro with endotoxin or proinflammatory cytokines leads to 
a marked increase in resistin production and vice versa, 
resistin strongly up-regulate IL-6 and TNF- production 
[6,18]. Thus resistin seems to act as an important 
member of the cytokine family with potent regulatory 
functions [18]. In preliminary studies, we found 
significantly higher levels of both pro-inflammatory 
cytokines (TNF-, IL-6, IL-8) and anti-inflammatory 
cytokine IL-10 in colon cancer patients as compared to 
healthy subjects (unpublished observations). However, in 
our study, there was no correlation between these 
cytokines and resistin levels, neither before, nor after 
surgery (data not shown). Collectively, our results showed 
a statistically significant increase in resistin serum levels 
but a lack of direct involvement of resistin in the systemic 
inflammatory response of patients with colon cancer or in 
disease progression. 
The association between leptin levels and the 
risk of colorectal cancer or adenoma has remained 
controversial. Although it has been suggested that in men, 
leptin may be associated with risk of colorectal adenomas 
[10,19] other studies found decreased leptin serum levels 
in colorectal cancer patients [11]. We found significantly 
lower serum leptin levels in colon cancer patients as 
compared to controls. Moreover, a significant negative 
correlation between leptin and T stage (P=0.021) was 
noted. When patients were divided in two subgroups 
according to tumor grade of differentiation, we found 
statistically significant lower serum leptin levels only for 
patients with poorly differentiated tumors and mucinous 
adenocarcinoma, additionally suggesting a gradually 
decrease in leptin levels with tumor aggressiveness. 
Others did not observe any significant differences for the 
fasting serum leptin levels in patients according to pTNM 
staging although a role for the leptin receptor is discussed 
in relation with the tumor immune response [20]. A 
plausible explanation for the inconsistencies in results 
includes differences in techniques for leptin detection, 
timing of phlebotomy and duration of fasting.  
Our study has some limitations. We had no 
information regarding body weight changes in the patients 
and controls before the sampling, and thus it was not 
possible to determine whether the changes in adipokines 
levels in the patients was caused by obesity before the 
sampling. Notably, several studies made the observations 
that adipokines concentration was not correlated with 
anthropometric measures of adiposity or weight loss in 
both control subject and cancer patients [6,11]. However, 
other studies confirm a strong correlation between leptin 
level and body mass index [20]. Also, if many more 
Table 3.  Serum adipokines concentration and P value in colon cancer patients according to tumor grade of differentiation Journal of Medicine and Life Vol. 3, No.4, October‐December 2010 
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patients were enrolled in this study, significant correlation 
between adipokines levels and clinicopathological 
features may have been detected. Despite these 
limitations we demonstrated that the levels of resistin and 
leptin were significantly different between colon cancer 
patients and controls. Resistin had significantly higher 
serum values in patients while leptin serum levels were 
lower as compared to controls. Leptin levels decreased 
gradually with tumor stage and aggressiveness. 
Moreover, for both adipocytokines, a statistically 
significant positive correlation between preoperative and 
postoperative values was noted. Taken together, these 
results of this study suggest that adipokines, in particular 
resistin and leptin might be involved in development and 
progression of colon cancer.  Obviously, further studies 
are needed to better elucidate which role adipocytokines 
have in determining disease progression.  
Acknowledgements  
This study was funded by Romanian Agency for 
Scientific Research (Contract grant number: 41-004).
 
References 
 
 
 
1.  Lang K, Ratke J. Leptin and 
Adiponectin: new players in the field 
of tumor cell and leukocyte 
migration. Cell Communication and 
Signaling. 2009; 7:27. 
2.  Galic S, Oakhill JS, Steinberg GR. 
Adipose tissue as an endocrine 
organ. Mol. Cell. Endocrinol 2010; 
316:129-139. 
3.  Nakajima TE, Yamada Y, Hamano 
T, Furuta K, Gotoda T, Katai H, 
Kato K, Hamaguchi T, Shimada Y. 
Adipocytokine levels in gastric 
cancer patients: resistin and visfatin 
as biomarkers of gastric cancer. J 
Gastroenterol. 2009; 44:685-690. 
4.  Wu MH, Chou YC, Chou WY, Hsu 
GC, Chu CH, Yu CP, Yu JC, Sun 
CA. Circulating levels of leptin, 
adiposity and breast cancer risk. 
British Journal of Cancer. 2009; 
100:578-582. 
5.  Gonullu G, Kahraman H, Bedir A, 
Bektas A, Y\ücel I. Association 
between adiponectin, resistin, insulin 
resistance, and colorectal tumors. 
Int J Colorectal Dis. 2010; 25:205–
212. 
6.  Sun C, Wu M, Chu C, Chou Y, Hsu 
G, Yang T, Chou W, Yu C, Yu J. 
Adipocytokine resistin and breast 
cancer risk [Internet]. Breast Cancer 
Res Treat. 2010; Epub ahead of 
print. 
7.  Howard JM, Pidgeon GP, 
Reynolds JV. Leptin and gastro-
intestinal malignancies. Obes Rev. 
2010; 1:1-12. 
8.  Hoda MR, Keely SJ, Bertelsen LS, 
Junger WG, Dharmasena D, 
Barrett KE. Leptin acts as a 
mitogenic and antiapoptotic factor 
for colonic cancer cells. Br J Surg. 
2007; 94:346-354. 
9.  Kim S, Keku TO, Martin C, 
Galanko J, Woosley JT, 
Schroeder JC, Satia JA, Halabi S, 
Sandler RS. Circulating levels of 
inflammatory cytokines and risk of 
colorectal adenomas. Cancer Res. 
2008; 68:323-328. 
10.  Stattin P, Lukanova A, Biessy C, 
Söderberg S, Palmqvist R, Kaaks 
R, Olsson T, Jellum E. Obesity and 
colon cancer: does leptin provide a 
link? Int. J. Cancer. 2004; 109:149-
152. 
11.  Kumor A, Daniel P, Pietruczuk M, 
Malecka-Panas E. Serum leptin, 
adiponectin, and resistin 
concentration in colorectal adenoma 
and carcinoma (CC) patients. Int J 
Colorectal Dis. 2009; 24:275-281. 
12. Filková M, Haluzík M, Gay S, 
Senolt L. The role of resistin as a 
regulator of inflammation: 
Implications for various human 
pathologies. Clin. Immunol. 2009; 
133:157-170. 
13.  Karapanagiotou E, Tsochatzis E, 
Dilana K, Tourkantonis I, Gratsias 
I, Syrigos K. The significance of 
leptin, adiponectin, and resistin 
serum levels in non-small cell lung 
cancer (NSCLC). Lung Cancer. 
2008; 61:391-397. 
14.  Wågsäter D, Mumtaz M, Löfgren 
S, Hugander A, Dimberg J. 
Resistin in Human Colorectal 
Cancer: Increased Expression 
Independently of Resistin Promoter 
−420C > G genotype. Cancer Invest. 
2008; 26:1008-1014. 
15.  Lerescu L, Tucureanu C, Caraş I, 
Sălăgeanu A. Cytokine profiling by 
multiplex immunoassay as an 
effective approach to assess 
immunomodulatory activity of 
bacterial product CANTASTIM. 
Roum Arch Microbiol Immunol. 
2006; 65:53-58. 
16.  R Development Core Team (2008): 
R: A Language and Environment for 
Statistical Computing. R Foundation 
for Statistical Computing, Vienna, 
Austria, URL http://www.R-
project.org; 2008. 
17.  Nakajima TE, Yamada Y, Hamano 
T, Furuta K, Matsuda T, Fujita S, 
Kato K, Hamaguchi T, Shimada Y. 
Adipocytokines as new promising 
markers of colorectal tumors. 
Adiponectin for colorectal adenoma, 
and resistin and visfatin for 
colorectal cancer. Cancer Sci. 2010; 
1:1-6. 
18.  Bokarewa M, Nagaev I, Dahlberg 
L, Smith U, Tarkowski A. Resistin, 
an adipokine with potent 
proinflammatory properties. J 
Immunol. 2005; 174:5789-5795. 
19.  Chia VM, Newcomb PA, Lampe 
JW, White E, Mandelson MT, 
McTiernan A, Potter JD. Leptin 
concentrations, leptin receptor 
polymorphisms, and colorectal 
adenoma risk. Cancer Epidemiol. 
Biomarkers Prev. 2007; 16:2697-
2703. 
20. Aloulou N, Bastuji-Garin S, Le 
Gouvello S, Abolhassani M, 
Chaumette MT, Charachon A, 
Leroy K, Sobhani I. Involvement of 
the Leptin Receptor in the Immune 
Response in Intestinal Cancer. 
Cancer Res. 2008; 68:9413-9422.
 